---
title: 'Management of adult patients with CMML undergoing allo-HCT: recommendations
  from the EBMT PH&amp;G Committee'
date: '2024-03-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38493484/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240318180743&v=2.18.0.post9+e462414
source: Blood
description: Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting
  with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic
  cell transplantation (allo-HCT) remains the only potentially curative option, but
  the inherent toxicity of this procedure makes the decision to proceed to allo-HCT
  challenging, particularly as patients with CMML are mostly older and comorbid. Therefore,
  the decision between a non-intensive treatment approach and allo-HCT represents
  ...
disable_comments: true
---
Chronic myelomonocytic leukemia (CMML) is a heterogeneous disease presenting with either myeloproliferative or myelodysplastic features. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option, but the inherent toxicity of this procedure makes the decision to proceed to allo-HCT challenging, particularly as patients with CMML are mostly older and comorbid. Therefore, the decision between a non-intensive treatment approach and allo-HCT represents ...